Robin Hood Ventures is a group of angel investors focused on early-stage and high-growth companies in the Greater Philadelphia region. The company generally invests $250,000 to $1,000,000. It invests in the IT services and software, life sciences and financial technology sectors.
BioCrossroads is a venture capital firm invests in life sciences industry based in Indiana. The firm operates early-stage life sciences venture funds investing in early-stage biotechnology, pharmaceutical, medical device, diagnostic, agtech, biotech and health information technology products and platforms.
Innovacorp is an incubator and an early-stage venture capital firm. The firm invests in the information technology, clean technology, life sciences and ocean technology sectors. The firm was founded in the year 1995 and it is based in Halifax, Canada.
Borealis Ventures is a venture capital firm headquartered in Hanover, New Hampshire and with an additional office in Boston, Massachusetts. The firm focuses on investing in companies operating within the healthcare space, including digital health and life sciences, and the "Built Environment" space, including construction technology, design & engineering software, 3D design, property tech and smart city software sectors.
CapDecisif Management is a venture capital firm based in Paris, France and was founded in 2001. The firm invests in companies operating in the technology, biotechnology, healthcare, information and communication, software, life sciences and engineering sectors.
Kreos Capital is an investment firm focuses on growth capital investments. The firm invests in the clean technology, communication, consumer, life sciences, semiconductor, hardware and software sectors. It was founded in 1998 and is based in England, London.
Lux Capital Management is a research-driven investment firm focused on founding, seed and early stage investments in the physical and life sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Our investment team has built over 20 companies from scratch. Lux's investment strategy ensures our portfolio companies are better connected, have deeper insight, and command industry leadership faster than their competitors.
Andy Palmer is a serial entrepreneur who specializes in accelerating the foundation and growth of early-stage, mission-driven companies. He has helped start, fund or found more than 50 innovative companies in technology, health care and the life sciences. Andy founded Koa Lab, a start-up fund in the heart of Harvard Square, Cambridge, Mass.; and co-founded Tamr, with Turing Award winner MIT professor Michael Stonebraker. Andy was named Angel of the Year in the New England Venture Capital Association‘s 2013 NEVY Awards.
As a Managing Director at H.I.G. BioVentures, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, and Clarus Therapeutics. Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices. Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.
Vulcan Capital is a private equity and venture capital firm and investment arm of Paul Allen based in Seattle, Washington. The firm focuses on investing in all stages of corporate development through leveraged buyouts, growth capital, turnarounds and early-stage venture capital. The firm invests in the financial services, internet technology, life sciences, media, communication and consumer sectors. It was established in 2003 and operates as an investment arm of Vulcan.
WRF Capital is the venture capital arm of Washington Research Foundation and it specializes in early-stage investments. The firm focuses on investing in companies based in Washington. While actively seeking investments in companies operating in life sciences and enabling technologies, the firm on an exceptional basis invest in companies in the physical sciences, energy, and information technology sectors. The firm was founded in 1981 and is based in Seattle, Washington.
Founded in 1973, Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. The company invests across all stages of company development including early and late-stage venture financing, growth equity, and public companies. With offices in London, Boston and Menlo Park, Abingworth has backed more than 100 developing life science/medical businesses, over two-thirds of which have gone public, merged, or been acquired. Abingworth has funds under management of more than $1.25 billion. The firm has raised eleven funds since it was founded in 1973, the last nine of which have been entirely dedicated to life sciences and healthcare. Abingworth's investments are based in the U.S. and Europe including the U.K., Belgium, Denmark, France, Germany, Holland and Sweden. The firm's investments range from $20-80 million over more than one round of financing. In February 2014, the firm announced the final closing of its POUND 225M ($375M) fund, Abingworth Bioventures VI (ABV VI). ABV VI is Abingworth's 10th life sciences fund.